Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies

A. Goldhirsch, R. Gelber

Research output: Contribution to journalArticle

Abstract

The Ludwig Breast Cancer Study Group conducted four concomitant trials involving adjuvant chemotherapy and endocrine therapy. In Ludwig I, adjuvant combination chemotherapy was used with or without prednisone to treat premenopausal and perimenopausal women with metastases in 1-3 axillary lymph nodes. The impact of adding low-dose continuous prednisone (7.5 mg/day) to an adjuvant, chemotherapy regimen of cyclosphamide, methotrexate, and 5-fluorouracil (CMF) was investigated in a randomized trial of 491 premenopausal and perimenopausal patients with operable breast cancer and metastases in 1-3 axillary lymph nodes. As a consequence of lower hematologic toxicity, a significantly higher dose of CMF could be administered with added prednisone (P

Original languageEnglish
Pages (from-to)55-70
Number of pages16
JournalNCI Monographs
VolumeNo. 1
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies'. Together they form a unique fingerprint.

  • Cite this